Compare EVO & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | EOLS |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 568.6M | 529.1M |
| IPO Year | 2007 | 2018 |
| Metric | EVO | EOLS |
|---|---|---|
| Price | $1.66 | $7.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $4.17 | ★ $15.00 |
| AVG Volume (30 Days) | 153.5K | ★ 658.0K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | N/A | $12.44 |
| Revenue Next Year | $20.51 | $17.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $1.50 | $3.86 |
| 52 Week High | $4.27 | $9.31 |
| Indicator | EVO | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 45.13 |
| Support Level | $1.50 | $7.59 |
| Resistance Level | $1.97 | $8.47 |
| Average True Range (ATR) | 0.05 | 0.29 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 76.00 | 29.89 |
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.